U.S. Army Captain Michael Kelvington, commander of the Battle company, 1-508 Parachute Infantry battalion, 4th Brigade Combat Team, 82nd Airborne Division, bows next to remains of Gulam Dostager, a member of Afghan Local Police who was killed in the blast of an Improvised Explosive Device (IED) during the joint Tor Janda (Black Flag in Pashtu) operation, in Zahri district of Kandahar province, southern Afghanistan May 25, 2012.  REUTERS/Shamil Zhumatov  (AFGHANISTAN - Tags: MILITARY CIVIL UNREST CONFLICT TPX IMAGES OF THE DAY)

Reuters Photojournalism

Our day's top images, in-depth photo essays and offbeat slices of life. See the best of Reuters photography.  See more | Photo caption 

Members of the U.S. Navy Blue Angels fly over the World Trade Center in lower Manhattan as part of the 25th annual Fleet Week celebration in New York, May 23, 2012.  REUTERS/Eduardo Munoz (UNITED STATES - Tags: MILITARY ANNIVERSARY TPX IMAGES OF THE DAY)

Fleet Week

The U.S. Navy takes Manhattan for a week.  Slideshow 

Photo

The SpaceX mission

A privately owned unmanned rocket blasts off on a mission to be the first commercial flight to the International Space Station.  Slideshow 

Roche reports progress in breast cancer treatment

Related Topics

A radiologist examines breast X-rays after a cancer prevention medical check-up at the Ambroise Pare hospital in Marseille, southern France, on April 3, 2008. REUTERS/Jean-Paul Pelissier

A radiologist examines breast X-rays after a cancer prevention medical check-up at the Ambroise Pare hospital in Marseille, southern France, on April 3, 2008.

Credit: Reuters/Jean-Paul Pelissier

ZURICH | Wed Dec 9, 2009 6:56am EST

ZURICH (Reuters) - Roche Holding AG said on Wednesday three studies on its drugs used to treat early and advanced breast cancer showed good results.

The Swiss drugmaker, the world's largest maker of cancer drugs, was due to present the results in coming days at the San Antonio Breast Cancer Symposium.

Roche said it would present five-year follow-up data from two studies into the use of Herceptin in early breast cancer which sought to answer questions about the best way of giving patients the treatment.

It will also present a study into the use of Avastin as a second-line treatment of advanced breast cancer.

Finally, it is also presenting new data from a Phase II study into the use of trastuzumab-DM1 for very advanced breast cancer.

(Editing by David Holmes)

Related Quotes and News

Company
Price
Related News
Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.